Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)

Trials by Status

not_yet_recruiting125%
completed250%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_4

SGLT2 Inhibitor Utilization Re-perfusion Therapy

NCT06858436
withdrawnnot_applicable

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

NCT03298009
completednot_applicable

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

NCT05764811
completedphase_3

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

NCT01381900

Clinical Trials (4)

Showing 4 of 4 trials
NCT06858436Phase 4

SGLT2 Inhibitor Utilization Re-perfusion Therapy

Not Yet Recruiting
NCT03298009Not Applicable

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Withdrawn
NCT05764811Not Applicable

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Completed
NCT01381900Phase 3

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4